UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016009
Receipt number R000018605
Scientific Title The study of the efficiency of Keishibukuryogankayokuinin on acne vulgaris.
Date of disclosure of the study information 2014/12/19
Last modified on 2016/11/01 11:46:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study of the efficiency of
Keishibukuryogankayokuinin on acne
vulgaris.

Acronym

The study of the efficiency of
Keishibukuryogankayokuinin on acne
vulgaris.

Scientific Title

The study of the efficiency of
Keishibukuryogankayokuinin on acne
vulgaris.

Scientific Title:Acronym

The study of the efficiency of
Keishibukuryogankayokuinin on acne
vulgaris.

Region

Japan


Condition

Condition

Acne vulgaris

Classification by specialty

Dermatology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate efficiency of Keishibukuryogankayokuinin in acne patients.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The decrement of inflammatory of acne lesions
The decrement of non-inflammatory of acne lesions
Patients QOL(SKINDEX-16,Syndromes presenting indefinite complaints)
Patients satisfaction(Visual analog scale)

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The treatment with medicine for external use with Oral Administration of keishibukuryogankayokuinin(2.5g t.i.d before meals)for 12 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

1)Patients who have inflammatory of acne lesions more than 6 counts on one side of their faces.
2)Patients for whom oral administration was possible.
3)Patients who agreed with their written informed consent

Key exclusion criteria

1)Patients with serious complications (liver,kidney,heart,blood,or metabolic disorders)
2)Steroid acne,Drug-induced acne,
Necrotizing acne, Occupational acne.
3)Patients who administrated steroid drugs on their whole body.
4)Women who are pregnant, might be pregnamt or lactating or planning a pregnancy.
5)Patients who received drugs prohibited for concomitant use within 1 week before the registration of this study.
6)Patients who participated in clinical trial within 1 month before the registration of this study.
7)Patients taking or planning chemical treatment or laser treatment in this study period.
8)Patients with history of hypersensitivity to traditional Japanese medicine.
9)Patients considered inappropriate by the study investigator

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toshitatsu Nogita

Organization

Shinjuku Minamiguchi Dermatology Skin Clinic

Division name

Director

Zip code


Address

1-18-7 Nishishinjyuku Shinjyuku-ku Tokyo, Japan

TEL

03-3343-4103

Email

nogita@hifuka.com


Public contact

Name of contact person

1st name
Middle name
Last name Toshitatsu Nogita

Organization

Shinjuku Minamiguchi Dermatology Skin Clinic

Division name

Director

Zip code


Address

1-18-7 Nishishinjyuku Shinjyuku-ku Tokyo, Japan

TEL

03-3343-4103

Homepage URL


Email

nogita@hifuka.com


Sponsor or person

Institute

Shinjuku Minamiguchi Dermatology Skin Clinic

Institute

Department

Personal name



Funding Source

Organization

TSUMURA & CO.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 12 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 11 Month 21 Day

Date of IRB


Anticipated trial start date

2015 Year 01 Month 05 Day

Last follow-up date

2016 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 12 Month 19 Day

Last modified on

2016 Year 11 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018605


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name